RESEARCH ARTICLE

High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort

Alan T. Clarke¹*, Paul C. D. Johnson²,5, Gillian C. Hall³, Ian Ford², Peter R. Mills⁴

¹ Dept. of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, United Kingdom, 2 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom, 3 Grimsdyke House London, London, United Kingdom, 4 Dept. of Gastroenterology, Gartnavel General Hospital, Glasgow, United Kingdom, 5 Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom

* aclarke1972@gmail.com

Abstract

Background & Aims
Occasional risk of serious liver dysfunction and autoimmune hepatitis during atorvastatin therapy has been reported. We compared the risk of hepatotoxicity in atorvastatin relative to simvastatin treatment.

Methods
The UK GPRD identified patients with a first prescription for simvastatin [164,407] or atorvastatin [76,411] between 1997 and 2006, but with no prior record of liver disease, alcohol-related diagnosis, or liver dysfunction. Incident liver dysfunction in the following six months was identified by biochemical value and compared between statin groups by Cox regression model adjusting for age, sex, year treatment started, dose, alcohol consumption, smoking, body mass index and comorbid conditions.

Results
Moderate to severe hepatotoxicity [bilirubin >60μmol/L, AST or ALT >200U/L or alkaline phosphatase >1200U/L] developed in 71 patients on atorvastatin versus 101 on simvastatin. Adjusted hazard ratio [AHR] for all atorvastatin relative to simvastatin was 1.9 [95% confidence interval 1.4–2.6]. High dose was classified as 40–80mg daily and low dose 10–20mg daily. Hepatotoxicity occurred in 0.44% of 4075 patients on high dose atorvastatin [HDA], 0.07% of 72,336 on low dose atorvastatin [LDA], 0.09% of 44,675 on high dose simvastatin [HDS] and 0.05% of 119,732 on low dose simvastatin [LDS]. AHRs compared to LDS were 7.3 [4.2–12.7] for HDA, 1.4 [0.9–2.0] for LDA and 1.5 [1.0–2.2] for HDS.
Conclusions

The risk of hepatotoxicity was increased in the first six months of atorvastatin compared to simvastatin treatment, with the greatest difference between high dose atorvastatin and low dose simvastatin. The numbers of events in the analyses were small.

Introduction

In the UK the National Institute for Health and Care Excellence [NICE] has recommended that primary prophylaxis with atorvastatin should now be considered for all individuals between the age of 30 to 84 years with a 10 year cardiovascular risk score of 10% or greater [1]. This has been estimated to include about 25% of this population and would constitute mass medication of healthy individuals [2]. This guidance has stimulated controversy over possible adverse effects of statins in a healthy population [3] and the observation that more information is required. Statins are widely used and generally well tolerated. Adverse effects include myopathy, an increased incidence of diabetes and an increase in serum transaminases [4].

Raised serum transaminases of hepatic origin are seen in about 1–3% of individuals treated with statins but occasional more severe reactions can occur, with possible autoimmune hepatitis, resulting in hospitalisation and rare deaths [5–21]. Most studies looking at drug-induced liver disease related to statins have relied on results from registration clinical studies or self-reported adverse drug event registers [22–27] which may lead to under-reporting of events.

The UK General Practice Research Database [GPRD] offered an opportunity to retrospectively examine all patients within a large sample population commenced on statin therapy in a "real world setting" and allowed examination of the true incidence of severe biochemical abnormalities associated with the use of atorvastatin. The GPRD became the Clinical Practice Research Datalink [CPRD] in March 2012. Simvastatin was selected as the comparator to atorvastatin as it is the most commonly prescribed statin in the UK and has few reports of hepatotoxicity. Also the patient population prescribed the two drugs should be comparable eliminating many other possible variables.

Patients and Methods

Study Design

A retrospective cohort study of the UK GPRD was undertaken comparing two groups of patients commenced on atorvastatin or simvastatin between the 10-year period 1997 to 2006 with regard to the incidence of hepatic reactions within this group.

Study population

A total of 245,025 patients were identified on the GPRD who had a first prescription [index date] for atorvastatin or simvastatin during the period 1st of January 1997 to the 31st of December 2006. Patients had to be permanently registered with the practice for at least twelve months prior to the index date with no record of liver disease, alcohol-related diagnosis, statin prescription or biochemical evidence of liver dysfunction prior to index date Table 1. Further exclusion was made of patients under 18 years of age [n = 79] and patients with self-reported alcohol consumption > 50 units/week [n = 1571]. To avoid counting prevalent hepatotoxicity, all patients with a record of any of a list of selected liver-related conditions were censored 90 days preceding the date of that condition code. As a result 118 patients were not included in the...
final analysis. A further 1234 patients were also not included for having a code recording an alcohol-related diagnosis. This resulted in a final analysis population of 242,023 patients with 165,188 patients prescribed simvastatin and 76,835 patients prescribed atorvastatin. High dose was classified as 40–80mg daily and low dose 10–20mg daily. 

These patients were followed up until they either reached the end of the study period, changed or stopped their prescribed statin, altered the dose of statin moving between low and high dose groups, transferred out of their GP practice, died, or were within 90 days of having a code recording liver disease that could not be drug induced [a post-exclusion event]. A patient’s ‘on drug’ exposure period [defined by recorded prescriptions] ended either on the day preceding the first change of statin or dose, or, if the statin was stopped altogether, 28 days after the date of the last statin prescription [because 28 days was the most common gap between prescriptions]. This study reports data for the on-drug period only. Only 11% of patients on simvastatin and 26% of patients on atorvastatin were censored due to a change to the higher dose group during the six month period we analysed after initiation of therapy. Several potential confounding factors such as age, sex, serum cholesterol, BMI, calendar year of first prescription and comorbidity and baseline patient characteristics are shown in Table 2.

The General Practice Research Database group has obtained blanket ethics approval for observational studies using the General Practice Research Database and studies using the General Practice Research Database that result in publication require prior approval by the Independent Scientific Advisory Committee, Medicines & Healthcare products Regulatory Agency, 151 Buckingham Palace Road, London, SW1W 9SZ, UK England.

The study was approved by General Practice Research Database research ethics committee: Independent Scientific Advisory Committee Reference Number Protocol No. 08_039 [Applicant Dr Peter Mills].

The data from General Practice Research Database is rigorously checked prior to release to ensure it is anonymized with no patient identifiers. We did not approach patients directly for consent as the data was supplied with licensed consent to use the data given by the Secretary of State for Health.

| Table 1. Exclusion criteria for patient selection prior to index date of statin prescription. |
|-----------------------------------------------|
| Alcohol related diagnosis                     |
| Pre-existing liver disease                    |
| - acute or chronic viral hepatitis            |
| - autoimmune liver disease, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis |
| - extra-hepatic biliary obstruction           |
| - metastatic liver disease                    |
| - haemochromatosis                            |
| - liver biopsy or transplant                  |
| Abnormal liver function:                      |
| - bilirubin levels >25 μmol/L                 |
| - AST levels >120 U/L                         |
| - ALT levels >120 U/L                         |
| - Alkaline Phosphatase levels >300 U/L        |
| Previous prescription of any statin           |

doi:10.1371/journal.pone.0151587.001
Definition of outcomes

Hepatotoxicity was defined as first evidence of abnormal liver biochemistry with either a serum bilirubin \( \geq 40 \) \( \mu \text{mol/l} \), serum aspartate aminotransferase [AST) or alanine aminotransferase [ALT] \( \geq 120 \) U/l [3 x ULN] or serum alkaline phosphatase [ALP] > 2 x ULN or \( \geq 600 \) U/l. Our cut-off values were primarily based upon local laboratory levels and we used 3 times the upper limit of normal for AST/ALT, 2 x the upper limit of normal for ALP and a bilirubin of over 40 [higher than our laboratory upper limit of normal] to try to counter possible small differences in regional definitions of normal/abnormal enzyme levels.

Our primary endpoint was an episode of at least moderate hepatotoxicity which was a serum bilirubin \( \geq 60 \) \( \mu \text{mol/l} \), serum AST or ALT \( \geq 200 \) U/l [5 x ULN] or serum alkaline phosphatase > 4 x ULN or \( \geq 1200 \) U/l within the first six months of follow-up after initiation of therapy. Other secondary endpoints defined as mild or severe liver dysfunction are categorised in Table 3.

In patients with laboratory evidence of abnormal hepatic function as above, the results were divided into three subcategories. Any one laboratory result at any point will qualify for inclusion in that category.

Table 2. Baseline characteristics of patients on simvastatin and atorvastatin grouped by statin dose.

| Dose | Data Complete | Simvastatin 10–20 mg | Simvastatin 40–80 mg | Atorvastatin 10–20 mg | Atorvastatin 40–80 mg |
|------|---------------|---------------------|---------------------|-----------------------|-----------------------|
| Total number | 242023 | 100% | 120367 | 44821 | 72741 | 4094 |
| Age [years] | Mean [SD] | 100% | 66 [12] | 65 [12] | 64 [12] | 62 [13] |
| Sex | Male | 100% | 61299 [50.9%] | 24659 [55%] | 37341 [51.3%] | 2355 [57.5%] |
| BMI | Mean [SD] | 95% | 27.9 [5.2] | 28.3 [5.5] | 28.3 [5.3] | 28.2 [5.4] |
| Serum cholesterol [mmol/L] | Mean [SD] | 85% | 6.3 [1.1] | 6.2 [1.2] | 6.5 [1.2] | 6.5 [1.6] |
| Alcohol [U/wk] | Mean [SD] | 55% | 8.8 [9.5] | 9.3 [9.9] | 8.9 [9.6] | 10 [10.4] |
| Index year | Mean [SD] | 100% | 2003.5 [2.6] | 2005.1 [1.4] | 2003.2 [2.1] | 2004.9 [1.5] |
| Length of follow-up [years] | Mean [SD] | 100% | 1.9 [2.0] | 1.3 [1.2] | 2.4 [1.9] | 1.4 [1.3] |
| Medical history recorded | Myocardial Infarct | * | 9969 [8.3%] | 5146 [11.5%] | 5516 [7.6%] | 1088 [26.6%] |
| Coronary heart disease | * | 30158 [25.1%] | 8962 [20%] | 16953 [23.3%] | 1076 [26.3%] |
| Cerebrovascular disease | * | 12183 [10.1%] | 5459 [12.2%] | 6973 [9.6%] | 325 [7.9%] |
| Peripheral vascular disease | * | 3102 [2.6%] | 1097 [2.4%] | 1941 [2.7%] | 100 [2.4%] |
| Diabetes mellitus | * | 25755 [21.4%] | 9807 [21.9%] | 18807 [25.8%] | 636 [15.5%] |
| Hypertension | * | 62470 [51.9%] | 22559 [50.3%] | 36190 [49.7%] | 1696 [41.4%] |
| MI within 30 days prior to index date | * | 3587 [3%] | 3121 [7%] | 1990 [2.7%] | 808 [19.7%] |
| Any of MI, CHD, CVD, PVD | * | 44116 [36.6%] | 16872 [37.6%] | 25150 [34.6%] | 2076 [50.7%] |

SD—standard deviation.

*Medical history data completeness could not be calculated because non-occurrence could not be distinguished from non-recording of a condition

doi:10.1371/journal.pone.0151587.t002
Data Analysis

The risk of reaching the primary endpoint was compared between patients being prescribed atorvastatin and simvastatin by estimating hazard ratios with 95% confidence intervals [CI] from Cox proportional hazards regression models. We investigated the possibility that a difference in risk between atorvastatin and simvastatin might depend upon statin dose by testing for an interaction between prescribed statin and dose [high [40 to 80 mg] or low [10 to 20 mg]] and estimating hazard ratios for high- and low-dose atorvastatin and high dose simvastatin relative to low dose simvastatin.

Atorvastatin has been reported to be more effective than simvastatin at lowering cholesterol [28], and higher doses are more effective than lower doses [29], so patients with more severe vascular disease, higher cholesterol levels or drug-resistant hypercholesterolaemia are more likely to be prescribed atorvastatin and/or a high dose. We therefore expected to observe an association between both prescribed statin, dose and risk of hepatotoxicity even in the absence of a causal link [confounding by indication]. The statin-hepatotoxicity association is also expected to be confounded by secular trends in statin prescribing patterns. We mitigated the impact of confounders by adjusting hazard ratios for age in years [categorical: 18–50, 51–60, 61–70, 71–80, 81–90, ≥91], sex, year of first prescription [categorical: 1997–2001, 2002–2003, 2004–2006; boundaries were chosen to give approximately equal numbers of patients in each category], self-reported alcohol consumption in units/week [categorical: 0, 1–7, 8–14, 15–21, ≥22], smoking habit [never, former, current], serum cholesterol level in mmol/L [categorical: <5, 5–5.99, 6–6.99, ≥7], BMI in kg/m² [categorical: <25, 25–29.9, ≥30], histories of MI, coronary heart disease, cerebrovascular disease, diabetes and hypertension and time of MI prior to entry to the study [categorical: 0–30 days, 31 days-1 year, 1+ years, no history].

In addition to quantifying relative risks as hazard ratios, we estimated excess risk in terms of absolute numbers of events by two methods. First, we estimated the number of events per 1000 patient-years of follow-up in each group as the predicted probability of a patient suffering an event within six months [1 – S, where S is the probability of not experiencing an event within six months] multiplied by 200. Second, we estimated the number of patients that would need to be treated [NNT] to predict an additional instance of hepatotoxicity. The NNT statistic was calculated from the survival probabilities following equation 1 of Altman and Andersen [30]. It is equivalent to the number needed to treat to cause harm to one patient compared with control in a clinical trial, but differs in interpretation. For both analyses, survival probabilities were estimated from a Cox regression model adjusted to a "typical" patient, that is, one who falls into the most frequent category of each adjustment covariate [male, aged 61–70 years, never a smoker, alcohol consumption not known, serum cholesterol 6–6.99 mmol/L, BMI 25–29.9 kg/m², no history of MI, CHD or CVD, a history of hypertension and index year 2004–2006]. 95% confidence intervals for both statistics were estimated from 20,000 bootstrap replicates.

Because excluding patients with missing alcohol, serum cholesterol or BMI would have reduced the size of the available data by 53%, we chose instead to fit missing alcohol, serum cholesterol and BMI data as additional categories. We assessed the sensitivity of the results to

| Table 3. Categorisation of abnormal liver biochemistry recorded after index date. |
|---------------------------------------------------------------|
| **Hepatotoxicity** | **Mild** | **Moderate** | **Severe** |
| Bilirubin [μmol/L] | 40–59   | 60–79   | ≥80       |
| AST or ALT [U/L]  | 120–199 | 200–399 | ≥400      |
| Alkaline Phosphatase [U/L] | 2–4 x ULN | 4–6 x ULN | >6 x ULN |

doi:10.1371/journal.pone.0151587.t003
this approach by re-estimating hazard ratios from the reduced data set. Smoking data could not be dealt with in this way because too few data were missing [N = 1205] to allow estimation of a hazard ratio, so patients with missing smoking data were excluded.

In an observational study it is never possible to adjust for all of the differences between patients that affect outcome. We therefore expected the adjusted hazard ratios to be biased by residual confounding. For example, patients are at increased risk of hepatotoxicity immediately following a myocardial infarction, and such patients are more likely to be prescribed atorvastatin and a high dose Table 2. We investigated this potential source of residual confounding by re-estimating the adjusted hazard ratios after the exclusion of patients with a myocardial infarction in the 30 days prior to first statin prescription. Another potential source of residual confounding is the fact that where no clinical history is recorded we do not know whether this is because the patient has no history or because the history has not been recorded in GPRD. We assessed the sensitivity of the adjusted hazard ratios to missing clinical history by excluding patients with no history of any of myocardial infarction, coronary heart disease, cerebrovascular disease or peripheral vascular disease. Where the numbers in the excluded subgroup were sufficient, we tested for a significant difference in the hazard ratios between the included and excluded subgroups.

Stratification of outcomes was performed according to statin dose to examine whether there was a dose-related effect in determining adverse outcome. All statistical analyses were performed using R version 2.13.0 [31].

**Results**

**Moderate to severe hepatotoxicity for simvastatin and atorvastatin**

71 [0.09%] of all 76411 patients on atorvastatin developed moderate or severe hepatotoxicity versus 101 [0.06%] of all 164407 patients on simvastatin in the first six months on treatment Table 4. The adjusted hazard ratio for atorvastatin relative to simvastatin was 1.9 [95% confidence interval 1.4–2.6; p<0.001].

**Moderate to severe hepatotoxicity in high versus low dose statin groups**

Hepatotoxicity was more common in patients on 40–80 mg than 10–20 mg of either statin [adjusted hazard ratio: 2.1; 95% CI 1.5–3.0; p<0.001] Table 5. The strength of the association with prescribed statin was stronger at high doses [interaction p<0.001], with hepatotoxicity

| Outcome                      | N   | Prescribed statin | P     |
|------------------------------|-----|-------------------|-------|
|                              |     | Simvastatin 164407| Atorvastatin 76411 |
| Hepatotoxicity               | 240818 | N [%] 407 [0.25%] | 245 [0.32%] |
| All grades                   |     | Unadj. HR 1 [ref]| 1.2 [1.0, 1.4]; 0.02 |
|                              |     | Adj. HR 1 [ref]  | 1.4 [1.2, 1.7]; <0.001 |
| Hepatotoxicity               | 240818 | N [%] 101 [0.06%]| 71 [0.09%] |
| Moderate to severe           |     | Unadj. HR 1 [ref]| 1.4 [1.0, 1.9]; 0.03 |
|                              |     | Adj. HR 1 [ref]  | 1.9 [1.4, 2.6]; <0.001 |

1205 [0.5%] patients with missing smoking data were excluded.

N = number

10.1371/journal.pone.0151587.t004

Table 4. Hazard ratio (HR) estimates [95% CI] for significant lab events associated with atorvastatin during the first 6 months therapy on treatment, relative to simvastatin.
being most common in patients on high dose atorvastatin. Moderate to severe hepatotoxicity occurred in 18 [0.44%] of 4075 high dose atorvastatin patients in comparison to 53 [0.07%] of 72336 patients on low dose atorvastatin, in 39 [0.09%] of 44675 patients on high dose simvastatin and 62 [0.05%] of 119732 patients on low dose simvastatin. Adjusted hazard ratios calculated relative to low dose simvastatin were 7.3 [4.2–12.7; \( p < 0.001 \)] for high dose atorvastatin, 1.4 [0.9–2.0; \( p = 0.095 \)] for low dose atorvastatin and 1.5 [1.0–2.2; \( p = 0.068 \)] for high dose simvastatin.

The distribution of liver function test severity levels among the 172 patients who experienced the primary endpoint of at least moderate hepatotoxicity with at least one of the four tests within 6 months of initiation of statin therapy is given in S1 Table.

Numbers needed to harm

The number of instances of moderate to severe hepatotoxicity per 1000 patient-years of follow-up was 0.9 [0.4–1.6] for low-dose simvastatin, 1.3 [0.6–2.3] for high-dose simvastatin, 1.2 [0.6–2.1] for low-dose atorvastatin and 6.5 [2.8–11.9] for high-dose atorvastatin. The excess risk of moderate to severe hepatotoxicity in the high dose atorvastatin group relative to low dose simvastatin translates to one additional event in six months per 359 [95% CI 188–912] patients treated. Cumulative incidence for moderate to severe hepatotoxicity for both atorvastatin and simvastatin and also for high versus low dose groups over the first six months after index dose is illustrated in Figs 1 and 2.

Effect/absence of significant vascular events on hepatotoxicity

The hazard ratios were not substantially affected by excluding patients suffering myocardial infarction in the 30 days prior to statin treatment [S2 Table], although we could not formally test this due to the low numbers of patients reaching an endpoint in the excluded subgroup [14/9438 patients with recent MI suffered hepatotoxicity]. Similarly, excluding patients with no history of vascular disease had no significant effect on the hazard ratios [interaction \( p = 0.355; S3Table \)].

Discussion

Hepatotoxicity was defined by laboratory test to include either a serum bilirubin >60 \( \mu \)mol/L, AST or ALT >200 U/L or alkaline phosphatase >1200 U/L. This increased risk was predominantly
Fig 1. Cumulative incidence of moderate-severe hepatotoxicity for atorvastatin and simvastatin [all doses] over 6 months after index dose.

doi:10.1371/journal.pone.0151587.g001

Fig 2. Cumulative incidence of moderate-severe hepatotoxicity for atorvastatin and simvastatin [high and low dose groups] over 6 months after index dose.

doi:10.1371/journal.pone.0151587.g002
experienced by patients on high dose atorvastatin, although the numbers of events in the analyses were small. 71 events [0.09%] were recorded on atorvastatin in comparison to 101 events [0.06%] on simvastatin with an adjusted hazard ratio of 1.9 for atorvastatin in comparison to simvastatin.

There have been 40 cases in the published literature of significant hepatotoxicity due to statins [12] with one of the larger case series, suggesting concern over atorvastatin, published by our group [5]. However, there is ongoing debate in the literature as to whether such concern over hepatotoxicity due to statins has any foundation with the major cardiovascular trials often quoted as demonstrating no safety concerns. It has been noted that the large trials devised for evaluating morbidity and mortality benefits of statins in treating cardiovascular disease were not designed with the intent of assessing the risk of drug-induced liver injury [DILI]. Similar rates of abnormal liver function tests were observed between placebo and treatment arms of large statin trials including EXCEL, the 4S study, the MIRACL study and WOSCOPS [32–35].

Since the large clinical statin trials, there have been studies looking specifically at the safety of statins with respect to drug-induced liver injury. Hepatic injury due to statins was reported by a group who analysed episodic reports of adverse drug reactions sent to the Swedish Adverse Drugs Reactions Advisory Committee between 1988 and 2010 [24]. Their definition of hepatotoxicity included transaminases five times the upper limit of normal or alkaline phosphatase at twice the upper limit of normal. They found 73 patients with hepatotoxicity of whom 30 [41%] were taking atorvastatin and 28 [38%] simvastatin with two deaths and one requirement for liver transplant. They demonstrated overall statin-related hepatotoxicity in 1.6/100,000 patient-years, with 2.9 events/100,000 patient-years for atorvastatin and 0.9 events/100,000 patient-years for simvastatin. Our systematic study demonstrated a more frequent rate of moderate to severe hepatotoxicity with 0.9 events/1000 patient-years for low-dose simvastatin [i.e. 90 events per 100000 patient-years compared to the rate of 0.9 events per 100000 patient years seen for simvastatin in the Swedish study], 1.3 events/1000 patient-years for high-dose simvastatin, 1.2 events/1000 patient-years for low-dose atorvastatin and 6.5 events/1000 patient-years for high-dose atorvastatin. The excess risk of moderate to severe hepatotoxicity for a patient on high dose atorvastatin group compared to a patient on low dose simvastatin translated to one additional hepatotoxic event in six months for every 359 patients treated. Our study had a significantly higher rate of events than seen in the Swedish study and may reflect our different methods and definitions. The Swedish study, as do most adverse event registries, relied on the healthcare reporting of adverse events [and could feasibly under-report the frequency of statin-related events] and cannot be compared directly with elevated liver function tests in routine testing recorded on the GPRD. They also calculated the incidence of statin-induced hepatotoxicity based on the total statin prescription data in Sweden during the study period whereas we report the prescription data only for the subjects in a well defined GPRD cohort. One final point of note is that the Swedish paper did include causality assessment by means of the RUCAM score which led to exclusion of some patients due to incomplete clinical data whereas we did not perform such an assessment.

Previous studies of drug-related adverse events have suggested that statins contribute to between approximately 1 to 3% of all drug-induced liver injury. A study by Bjornsson et al [25] reported on 784 cases of drug-induced liver injury and suspected statins in 8 [4 atorvastatin, 4 simvastatin] of these cases with two of the eight patients going to liver transplant and death respectively. Andrade et al [26] prospectively examined 461 cases of drug-induced liver injury reported to the Spanish Hepatotoxicity Registry, implicating statins in 18 cases [3%] and a similar proportion of drug-induced liver injury [3.4%] was reported by Chalasani et al [27].

Previous studies have shown severe adverse hepatic events related to statins to be infrequent. The Acute Liver Failure Study Group reported on 133 prospectively collected cases of acute liver failure due to drug-induced liver injury between 1998 and 2010 [36]. 2 patients
[1.5%] had taken atorvastatin, 2 had taken simvastatin and 2 had taken the now discontinued cerivastatin. Interestingly, high ANA titres were seen in cases due to cerivastatin and simvastatin, suggesting a possible drug-induced autoimmune phenomenon. Other groups have also highlighted an apparent link between statins and autoimmune hepatitis [37–42].

A comparative safety analysis of 49 trials involving 14236 patients looked at the effect of dosage on adverse events due to atorvastatin [43]. The incidence of any ALT or AST elevations greater than 3 times the upper limit of normal was 0.6% in the atorvastatin 10 mg group, 0.6% in the placebo group and 3.3% in the atorvastatin 80 mg group. The positive association observed in this study between atorvastatin dose and hepatotoxicity incidence mirrors our own findings.

A recent update by the Statin Liver Safety Task Force concluded that recorded hepatotoxicity due to all statins was still a rare event. The group reported that the FDA had conducted several post-marketing reviews of statins and hepatotoxicity from 2000 to 2009 using the Agency’s Adverse Event Reporting System [AERS] database. The reporting of statin-associated serious liver injury to the AERS database was extremely low [reporting rate of less than two per one million patient-years] [44]. This discrepancy with our own study may reflect the potential under-reporting of adverse events in registries discussed previously in our paper.

One of the weaknesses of our study was the high frequency of missing data due to variation among clinicians in recording data (Table 2). However, we assessed the impact of missing data using sensitivity analyses. Another weakness of retrospective GPRD studies is that there is inevitably variation in reference ranges for laboratory values between different practices. To address this we devised a set of laboratory criteria to reflect severe levels of liver injury. The degree of liver dysfunction to qualify as moderate hepatotoxicity was quite stringent to ensure that the large numbers with mild elevation of serum transaminases commonly seen with statins were not observed as an end-point. Another final point of note is that our events per patient-years calculation was based upon events recorded within six months of drug initiation. We analysed the initial six months as previous case series have demonstrated that the majority of idiosyncratic liver reactions are seen in the initial period after commencement of statin [12]. Given that our mean length of follow-up was up to 2.4 years for low dose atorvastatin, 1.9 years for low dose simvastatin, 1.4 years for high dose atorvastatin and 1.3 years for high dose simvastatin, any events per patient-year calculation based upon all observed follow-up may have been influenced by this variation in therapy duration between the different statin-dose groups.

In conclusion, patients on atorvastatin were found to have an overall increased risk of hepatotoxicity in comparison to those on simvastatin. This increased risk was predominantly experienced by patients on high dose atorvastatin with an incidence of biochemical hepatotoxicity of 6.5 per 1,000 patient-years. This risk of measured hepatic events was significantly higher than previously reported studies which were based upon healthcare reporting and may reflect under-reporting in such systems. Low dose statin therapy appears to be relatively safer than high dose atorvastatin in our study. However the absolute difference in risk is small.

Supporting Information

S1 Table. Distribution of liver function test severity levels among the 172 patients who experienced the primary endpoint of at least moderate hepatotoxicity with at least one of the four tests within 6 months of initiation of statin therapy.

(SDOCX)

S2 Table. Hazard ratio [HR] estimates [95% CI] for significant laboratory events associated with statin-dose combinations during the first 6 months therapy, relative to low dose.
**Atorvastatin Hepatotoxicity in Comparison to Simvastatin in UK GPRD**

**simvastatin.** 9438 patients with MI within 30 days prior to therapy initiation were excluded. (DOCX)

**S3 Table.** Hazard ratio [HR] estimates [95% CI] for significant lab events associated with statin-dose combinations during the first 6 months therapy, relative to low dose simvastatin. Only patients with a history of MI, CHD, CVD or PVD were included. (DOCX)

**Acknowledgments**

This study was funded by a grant awarded by the UK Medical Research Council for data extraction from the General Practice Research Database.

**Author Contributions**

Conceived and designed the experiments: AC PM IF. Analyzed the data: AC PJ GH IF PM. Wrote the paper: AC PJ GH IF PM.

**References**

1. Rabar S, Harker M, O’Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Brit Med J. 2014; 349:g4356 doi: 10.1136/bmj.g4356 PMID: 25035388
2. Goldacre B, Smeeth L. Mass treatment with statins. Brit Med J. 2014; 349:g4745 doi: 10.1136/bmj.g4745 PMID: 25056140
3. Godlee F. Statins and the BMJ. Brit Med J. 2014; 349:g5038 doi: 10.1136/bmj.g5038 PMID: 25103509
4. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. Brit Med J. 2014; 349:g3743 doi: 10.1136/bmj.g3743 PMID: 25035309
5. Clarke AT, Mills PR. Atorvastatin associated liver disease. Digest Liver Dis. 2006; 38:772–7
6. Perger L, Kohler M, Fattinger K, Flury R, Meier P, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003; 39:1096–7
7. Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med. 2002; 113:348–9 PMID: 12361829
8. Ridruejo E, Mando O. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol. 2002; 37:165–6 PMID: 12076881
9. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999; 353:1763–4
10. Jiménez-Alonso J, Osorio JM, Gutiérrez-Cabello F, de La Osa A, León L, García JD. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med. 1999; 159:1811–2
11. Geoghegan M, Smith V, Green JRB. Acute cholestatic hepatitis associated with atorvastatin. Gut. 2004; 53(Suppl. III):A123
12. Russo MW, Scobery M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009; 29:412–422 doi: 10.1055/s-0029-1240010 PMID: 19826975
13. LaRosa John C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425–1435 PMID: 15755765
14. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437–2445. PMID: 16287954
15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495–1504. PMID: 15007110
16. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307–1316. PMID: 15337732
17. Gershovich OE, Lyman AE. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy. 2004; 24(1):150–4 PMID: 14740794
18. De Castro ML, Baz A, De Luaces C, Perez R et al. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol. 2006; 29(1):21–4 PMID: 16393626
19. Van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005; 42(5):402–4
20. Lata S, Chudy B. Cholestatic hepatitis caused by simvastatin in a 67 year old patient. Przegl Lek. 2006; 63(7):97–8
21. Currascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatic toxicity? J Hepatol. 2015. 62 (3):751–2 doi: 10.1016/j.jhep.2014.11.019 PMID: 25463547
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301–7 PMID: 7566020
23. Russo MW, Galanko JA, Shrestha R., Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplant. 2004; 10:1018–1023
24. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012; 56:374–380. doi: 10.1016/j.jhep.2011.07.023 PMID: 21889469
25. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005; 42:481–489 PMID: 16025496
26. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129:512–521 PMID: 16083708
27. Chalasani N, Fontana RJ, Bonkowski HL, Watkins PB, Davern T, Serrano J et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135:1924–1934 doi: 10.1053/j.gastro.2008.09.011 PMID: 18955056
28. Jones P et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvasatin in patients with hypercholesterolemia [The CURVES Study]. Am J Cardiol. 1996; 81:582–587 PMID: 9514545
29. Nawrocki JW, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia. Evaluation of Lovastatin [EXCEL] study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991; 151:43–9 PMID: 1985608
30. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. Brit Med J. 1999; 319;1492 PMID: 10582940
31. R Development Core Team. R: A language and environment for statistical computing. 2011. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/
32. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA et al. Expanded Clinical Evaluation of Lovastatin [EXCEL] study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15: 678–682. PMID: 7749881
33. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet. 1994; 344:1383–1389 PMID: 7968073
34. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285:1711–8 PMID: 11277825
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301–7 PMID: 7566020
36. Reuben A., Koch DG, Lee WM. Drug-induced acute liver failure: Results of a US multicenter, prospective study. Hepatology, 2010; 52:2065–2076 doi: 10.1002/hep.23937 PMID: 20949552
37. Graziedel IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003; 12:409–412 PMID: 12765306
38. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003; 15:921–924 PMID: 12867804
39. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007; 21:17–24 PMID: 17207162

40. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005; 17:589–590 PMID: 15827453

41. Czaja AJ. Drug-induced autoimmune-like hepatitis. Digest Dis Sci 2011; 56: 958–976 doi: 10.1007/s10620-011-1611-4 PMID: 21327704

42. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006; 40:757–61 PMID: 16940892

43. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol.2006; 97:61–67. PMID: 16377285

44. Bays H, Cohen D, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology 2014; 8:S47–S57 doi: 10.1016/j.jacl.2014.02.011 PMID: 24793441